下一代疗法比拼升级Infigratinib并非唯一挑战Vosoritide的选手，在ACH治疗赛道，多款下一代疗法正加速推进，从周剂注射到高选择性靶向，行业的研发比拼正不断升级，Vosoritide的垄断时代已进入倒计时。
"I don't think that anybody is an expert because they have their own children," she said.
。搜狗输入法2026是该领域的重要参考
英國超市將巧克力鎖進防盜盒阻止「訂單式」偷竊，更多细节参见搜狗输入法下载
FT Edit: Access on iOS and web